Eli Lilly, Stocks to Buy

Is Eli Lilly and Company (LLY) the Top Stock to Buy According to Sustainable Insight Capital Management?
We recently published a list of Top 10 Stocks to Buy According to Sustainable Insight Capital Management. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other top stocks to buy according to sustainable insight capital management.
Citi Sticks to Their Buy Rating for Eli Lilly & Co (LLY)
Citi analyst Geoff Meacham reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,190.00. The
Eli Lilly and Company (NYSE:LLY) Stock Acquired Sen. Ron Wyden
Senator Ron Wyden (D-Oregon) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 21st, the Senator disclosed that they had bought between $50,001 and $100,000 in Eli Lilly and Company stock on January 22nd.
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including Mounjaro (for diabetes) and Zepbound (for weight loss). Together, those two products generated $5.4 billion in sales for Eli Lilly last quarter, or 40% of the top line.
Eli Lilly (LLY) Stockpiles Weight Loss Pill Ahead of Regulatory Approval
Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the
Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing loss
The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the world. Now, the pharma giant wants to reinvest its success with weight-loss meds into tackling some of the world’s toughest health challenges.
Lilly's next obesity drug serves up dramatic weight loss -- and side effects - report
Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say that while they have seen incredible weight loss, it has also come with its share of notable side effects.
Hosted on MSN1h
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...
FiercePharma4h
Lilly banks stockpile of oral GLP-1 drug with potential launch still more than a year away
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
Eli Lilly aims to invest in ‘big problems hiding in plain sight' using obesity windfall
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
New weight-loss drugs like Mounjaro are hot right now. Eli Lilly's CEO explains why they're so expensive.
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
Seeking Alpha3d
LLY Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...
labiotech5h
Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?
Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...